A Single-Center Experience With Tacrolimus LCP (Envarsus XR) in Pancreas Transplant Recipients

First World Consensus Conference on pancreas transplantation: Part II – recommendations

“…Data are available only for SPK transplantation and show that once‐a‐day tacrolimus formulation is associated with excellent patient and graft survival, and that patients can be safely converted from standard tacrolimus to long‐acting tacrolimus. 270 , 271 , 272 , 273 …”

“…Reported experience with the use of once‐a‐day tacrolimus formulation in pancreas transplantation is limited. Data are available only for SPK transplantation and show that once‐a‐day tacrolimus formulation is associated with excellent patient and graft survival, and that patients can be safely converted from standard tacrolimus to long‐acting tacrolimus 270–273 …”

“…Data are available only for SPK transplantation and show that once-a-day tacrolimus formulation is associated with excellent patient and graft survival, and that patients can be safely converted from standard tacrolimus to long-acting tacrolimus. [270][271][272][273] In comparison with cyclosporine, experts agreed that the use of tacrolimus is prevalent in all pancreas transplant categories and is associated with superior immunologic outcomes. No conclusion could be drawn on the comparative efficacy of once-a-day vs. twice-a-day tacrolimus formulations due to lack of supporting data.…”

Utilization of LCP-Tacrolimus (Envarsus XR) in Simultaneous Pancreas and Kidney Transplant Recipients

“…Information about LCPT and pancreas transplantation is limited. 10 As such, this early, single-center experience is an important contribution to the literature. While the number of subjects does not allow for definitive conclusions, this observational study does provide an insight into LCPT usage in SPK recipients.…”

Alternatives to immediate release tacrolimus in solid organ transplant recipients: When the gold standard is in short supply

“…In this small population, less aggressive empiric adjustments from IR-TAC to LCPT were needed than suggested by the manufacturer. 33 Limited data exist for LCPT in thoracic transplant recipients. A pharmacokinetic study of 20 stable lung transplant recipients converted from XL-TAC to LCPT demonstrated the conversion to be safe and effective up to six months after transplant.…”